Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

News Trending Portfolio

TOOLS

Top Smart Score Stocks

STOCKS

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

TOT BIOPHARM International Co. Ltd. (HK:1875)

HKEX:1875

1875

TOT BIOPHARM International Co. Ltd.

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Holding HK:1875?

Track your performance easily

Link Broker

TOT BIOPHARM International Co. Ltd. (1875) Stock Price & Analysis

0 Followers

1875 Stock Chart & Stats

Advanced Chart >

Day’s RangeHK$0 - HK$0

52-Week RangeHK$0.70 - HK$2.79

Previous CloseHK$1.89

Volume0.00

Average Volume (3M)359.32K

Market Cap

HK$1.46B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)121.2

Beta0.31

Next Earnings

Mar 25, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.01

Shares OutstandingN/A

10 Day Avg. Volume33,560

30 Day Avg. Volume359,325

Standard Deviation0.09

R-Squared0.00644

Alpha-0.01

Financial Highlights & Ratios

Price to Book (P/B)0.00

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$2.40

Price Target Upside26.98% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

TOT BIOPHARM International Co. Ltd. News

PremiumCompany Announcements

TOT BIOPHARM Sees 49% Revenue Surge in 2024

12d ago

1875

PremiumCompany Announcements

TOT BIOPHARM Posts Strong Growth and Profit

3M ago

1875

PremiumCompany Announcements

TOT BIOPHARM Schedules Key Financial Review Meeting

4M ago

1875

PremiumCompany Announcements

TOT BIOPHARM Shareholders Back All Resolutions

5M ago

1875

PremiumCompany Announcements

TOT BIOPHARM Reschedules AGM and Adds Election Agenda

6M ago

1875

PremiumCompany Announcements

TOT BIOPHARM Plans New Share Award Scheme

6M ago

1875

PremiumCompany Announcements

TOT BIOPHARM Plans New Incentive Scheme

6M ago

1875

PremiumCompany Announcements

TOT BIOPHARM Announces Upcoming Annual Meeting

6M ago

1875

See More HK:1875 News >

1875 FAQ

What was TOT BIOPHARM International Co. Ltd.’s price range in the past 12 months?

TOT BIOPHARM International Co. Ltd. lowest stock price was HK$0.70 and its highest was HK$2.79 in the past 12 months.

What is TOT BIOPHARM International Co. Ltd.’s market cap?

Currently, no data Available

When is TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date?

TOT BIOPHARM International Co. Ltd.’s upcoming earnings report date is Mar 25, 2025 which is in 121 days.

How were TOT BIOPHARM International Co. Ltd.’s earnings last quarter?

TOT BIOPHARM International Co. Ltd. released its earnings results on Aug 13, 2024. The company reported HK$0.043 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.043.

Is TOT BIOPHARM International Co. Ltd. overvalued?

According to Wall Street analysts TOT BIOPHARM International Co. Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does TOT BIOPHARM International Co. Ltd. pay dividends?

TOT BIOPHARM International Co. Ltd. does not currently pay dividends.

What is TOT BIOPHARM International Co. Ltd.’s EPS estimate?

TOT BIOPHARM International Co. Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does TOT BIOPHARM International Co. Ltd. have?

TOT BIOPHARM International Co. Ltd. has 772,787,900 shares outstanding.

What happened to TOT BIOPHARM International Co. Ltd.’s price movement after its last earnings report?

TOT BIOPHARM International Co. Ltd. reported an EPS of HK$0.043 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of TOT BIOPHARM International Co. Ltd.?

Currently, no hedge funds are holding shares in HK:1875

---

TOT BIOPHARM International Co. Ltd. Stock Smart Score

Unlock Smart Score

Analyst Consensus

Moderate Buy

Average Price Target:
HK$2.40 (26.98% Upside)

Technicals

Fundamentals

Return on Equity

1.27%

Trailing 12-Months

Asset Growth

6.33%

Trailing 12-Months

Top Smart Score Stocks >

1875 Stock 12 Month Forecast

Average Price Target

HK$2.40

▲(26.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"HK$0","3":"HK$3","0.75":"HK$0.75","1.5":"HK$1.5","2.25":"HK$2.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$2.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$2.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$2.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,0.75,1.5,2.25,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.86,1.9015384615384616,1.9430769230769231,1.9846153846153847,2.0261538461538464,2.0676923076923077,2.109230769230769,2.1507692307692308,2.1923076923076925,2.233846153846154,2.275384615384615,2.316923076923077,2.3584615384615386,{"y":2.4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.86,1.9015384615384616,1.9430769230769231,1.9846153846153847,2.0261538461538464,2.0676923076923077,2.109230769230769,2.1507692307692308,2.1923076923076925,2.233846153846154,2.275384615384615,2.316923076923077,2.3584615384615386,{"y":2.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.86,1.9015384615384616,1.9430769230769231,1.9846153846153847,2.0261538461538464,2.0676923076923077,2.109230769230769,2.1507692307692308,2.1923076923076925,2.233846153846154,2.275384615384615,2.316923076923077,2.3584615384615386,{"y":2.4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.95,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.96,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.6,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.59,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.56,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.74,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.17,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.88,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.99,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.81,"date":1723766400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.99,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

Viva Biotech Holdings

―

6855

Ascentage Pharma Group International

―

2266

Lai Si Enterprise Holding Ltd.

―

9926

Akeso, Inc.

―

Compare HK:1875 Stocks >

Best Analysts Covering 1875

1 Year

Chris LuiJefferies

1 Year Success Rate

2/3 ratings generated profit

1 Year Average Return

+5.50%

reiterated a buy rating last month

Copying Chris Lui's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +5.50% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing